Latest Grant Funding News

Delorean Corporation has received a $2.7 million milestone payment from ARENA, advancing its SA1 Salisbury bioenergy facility toward renewable gas production underpinned by a key offtake deal with Origin Energy.

Australian Vanadium Limited has received a $4.9 million milestone payment from the federal government, advancing its integrated vanadium project aimed at supporting domestic battery energy storage solutions.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Altamin Limited has announced a $6.46 million capital raising via a pro rata entitlement offer to fund development of its lithium-potash Lazio Project and zinc-lead Gorno Project in Italy. The majority shareholder Victor Smorgon Group has committed strongly, underpinning the raise.

Vulcan Energy has obtained the crucial permit to build and operate its Central Lithium Plant in Frankfurt, marking a significant milestone in Europe's push for sustainable, domestic lithium production to support electric vehicle battery manufacturing.

Livium Ltd has inked a term sheet with the University of Melbourne to exclusively commercialise innovative microwave technology for rare earth elements extraction, promising high recovery rates and major energy savings.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.

First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.